Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2018 Jan 23;319(4):404-406.
doi: 10.1001/jama.2017.20653.

Characteristics of Interim Publications of Randomized Clinical Trials and Comparison With Final Publications

Steven Woloshin  1 , Lisa M Schwartz  1 , Pamela J Bagley  2 , Heather B Blunt  2 , Brian White  3
Affiliations
Comparative Study

Characteristics of Interim Publications of Randomized Clinical Trials and Comparison With Final Publications

Steven Woloshin et al. JAMA. .

Abstract

This study describes the number of interim reports of ongoing randomized trials published between 2006 and 2015, the reasons for interim reporting, and differences in the abstract conclusions between interim and final publications.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Drs Woloshin and Schwartz report having served as medical experts in testosterone litigation and were the cofounders of Informulary Inc, a company that provided data about the benefits and harms of prescription drugs, which ceased operations in December 2016. No other disclosures were reported.

Comment in

  • doi: 10.1001/jama.2017.20606

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Stephens RJ, Langley RE, Mulvenna P, Nankivell M, Vail A, Parmar MK. Interim results in clinical trials: do we need to keep all interim randomised clinical trial results confidential? Lung Cancer. 2014;85(2):116-118. - PubMed
    1. Wang H, Rosner GL, Goodman SN. Quantifying over-estimation in early stopped clinical trials and the “freezing effect” on subsequent research. Clin Trials. 2016;13(6):621-631. - PMC - PubMed
    1. Bassler D, Briel M, Montori VM, et al. ; STOPIT-2 Study Group . Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA. 2010;303(12):1180-1187. - PubMed
    1. Counsell N, Biri D, Fraczek J, Hackshaw A. Publishing interim results of randomised clinical trials in peer-reviewed journals. Clin Trials. 2017;14(1):67-77. - PubMed
    1. Petzer AL, Wolf D, Fong D, et al. . High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 “ISTAHIT” study. Haematologica. 2010;95(6):908-913. - PMC - PubMed

Publication types